A Rat Model of Ascending Uncomplicated Urinary Tract Infection for Anti-Infective Efficacy Studies

Urinary tract infections are among the most common bacterial illnesses affecting people worldwide, causing significant discomfort and, in severe cases, leading to life-threatening complications. The bacteria responsible for most of these infections, a type of E. coli found in the gut, typically enter the body through the urethra and travel upward to the bladder, where they cause cystitis. If left unchecked, the infection can ascend further into the kidneys, resulting in a more serious condition known as pyelonephritis. As drug-resistant strains of these bacteria become more common, scientists urgently need new ways to test potential medicines. To do this, they rely on animal models that mimic human disease, but the choice of animal matters greatly. Mice are frequently used, yet their small size and unique anatomy make it difficult to study how drugs move through the body or to administer treatments in ways that resemble human medical practice. Rats, with their larger bodies and urinary systems that function more like our own, offer a promising alternative, but researchers have struggled to create a consistent and reliable method for infecting them without causing unnatural complications.

In a recent study, researchers at the Murdoch Children's Research Institute in Australia developed a refined method for creating a urinary tract infection in adult female rats that closely follows the natural path of the disease. The team focused on a specific, well-known strain of uropathogenic E. coli called CFT073, which is famous for causing kidney infections in humans. Their goal was to establish a model where the bacteria could travel from the bladder to the kidneys naturally, without forcing them there through unnatural means. To achieve this, the scientists first compared two common types of rats: Sprague Dawley and Wistar. They found that while both could be infected, the Wistar rats provided a more stable and predictable result, with less variation between individual animals. This stability is crucial for testing new drugs, as it ensures that differences in treatment outcomes are due to the medicine itself rather than random biological fluctuations.

The researchers discovered that the way they prepared the bacteria before infection was just as important as the choice of rat. By growing the bacteria in a specific, non-shaking environment, they encouraged the microbes to produce more of a hair-like structure on their surface called type 1 fimbriae. These structures act like tiny grappling hooks, allowing the bacteria to stick firmly to the bladder wall. When the team used these "hooked" bacteria to infect the rats, the results were striking. The bacteria successfully colonized the bladder and, within a day, traveled upward to infect the kidneys in a manner that mimics how the disease progresses in humans. This was a significant improvement over previous attempts, which often failed to establish kidney infections or required such large doses of bacteria that the infection felt artificial. The new method allowed the infection to take hold with a much smaller number of bacteria, making the model both more realistic and more sensitive to testing.

To prove that this new model could be used to evaluate treatments, the researchers administered a single intravenous dose of ciprofloxacin, a common antibiotic, to the infected rats. The results were rapid and effective. Within two hours of treatment, the drug began to kill the bacteria, and by twenty-four hours, the number of bacteria in the urine, bladder, and kidneys had dropped dramatically. In the kidneys specifically, the bacterial load was reduced by more than four orders of magnitude compared to untreated animals, demonstrating that the drug could effectively clear the infection from the upper urinary tract. The study also examined the physical damage caused by the infection. Infected rats showed signs of swelling and an influx of immune cells into the bladder tissue, which are hallmarks of the body's fight against the bacteria. After treatment with the antibiotic, this tissue damage and swelling were significantly reduced, confirming that the drug not only killed the bacteria but also helped the body heal.

Beyond simply counting bacteria and looking at tissue under a microscope, the team analyzed the chemical signals the rats' bodies produced during the infection. They found that the infection triggered a localized inflammatory response, characterized by an increase in specific proteins that signal the immune system to act. Interestingly, when the rats were treated with the antibiotic, the levels of these inflammatory signals actually increased further before settling down. This suggests that as the drug kills the bacteria, the release of bacterial debris triggers an additional, temporary surge in the immune response. This finding is important because it highlights that treating an infection is a dynamic process where the body's reaction to the dying bacteria is just as complex as the reaction to the living ones.

This work establishes a robust and reproducible tool for the future development of new antibiotics. By using Wistar rats and a specific method of preparing the bacteria, the researchers have created a system that allows scientists to test intravenous drugs in a way that closely mirrors human physiology. This is particularly valuable because many new antibiotics in development are designed to be given through a vein, and testing them in mice often presents technical hurdles that this rat model overcomes. While the study used a single strain of bacteria and a limited number of time points, the model successfully captures the essential features of an ascending urinary tract infection, from the initial colonization of the bladder to the spread to the kidneys and the subsequent response to treatment. As the world faces a growing crisis of drug-resistant infections, having reliable models like this one is essential for accelerating the discovery of the next generation of life-saving medicines.